Last reviewed · How we verify
Intravenous Ampicillin followed by Oral Amoxicillin
Intravenous Ampicillin followed by Oral Amoxicillin, marketed by Sheba Medical Center, is a combination therapy with a key composition patent expiring in 2028. The therapy leverages a well-established mechanism to address primary indications, offering a robust treatment option in the market. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Intravenous Ampicillin followed by Oral Amoxicillin |
|---|---|
| Sponsor | Sheba Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Azithromycin and Ampicillin for Late PPROM (PHASE4)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis. (PHASE4)
- LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media (NA)
- Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: